Eijkman-Oxford Clinical Research Unit (EOCRU)

Eijkman-Oxford Clinical Research Unit (EOCRU)

Consultation date: 07 May 2015

Malaria elimination strategy

The Eijkman-Oxford Clinical Research Unit (EOCRU) was created in 2007 by agreement between the Eijkman Institute for Molecular Biolology (EIMB, Ministry of Science & Technology) and the University of Oxford to collaborate on clinical, laboratory, and field research on infectious diseases of public health importance in Indonesia. EIMB and EOCRU undertake joint collaborative research endeavors principally in the field of malariology, and especially involving the parasite species Plasmodium vivax

Together with partners in the Faculty of Medicine, University of Indonesia and the health services division of the Indonesian Army, EOCRU and EIMB have developed a clinical trial model for clinical interventions for preventing and treating malaria – young soldiers based in malaria-free areas of Java being deployed to heavily malarious outer islands of Indonesia for routine duties, but who return to Java after 6 months to a year. The clinical trials team composed of all these partners have successfully executed 2 trials of primaquine therapy against relapse of vivax malaria, and now plan for a third involving tafenoquine, all of which have been genrously funded by the Medicines for Malaria Venture, Geneva.

The Unit is a partner in the IMPROV multi-centre clinical trial of primaquine against relapse of vivax malaria based at the Oxford unit in Bangkok (MORU). The Unit also conducts basic laboratory bench, clinical, and field research on the diagnosis and epidemiology of glucose-6-phosphate dehydrogenase deficiency (G6PDd), and polymorphisms in cytochrome P450 2D6 (CYP2D6). Both of these factors profoundly impact the prevention and treatment of Plasmodium vivax malaria.